Related Experiment Video
Updated: Oct 17, 2025
04:09
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
477
Subxiphoid thoracoscopic thymectomy for myasthenia gravis
Yuanyuan Liu1, Jinghao Zhang1, Wenbin Wu2
1Department of Respiratory and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China.
Interactive Cardiovascular and Thoracic Surgery
|October 9, 2021
Summary
Subxiphoid thoracoscopic thymectomy shows technical feasibility for myasthenia gravis treatment. However, complete remission rates were low, indicating a need for more research.
Area of Science:
- Neurosurgery
- Thoracic Surgery
- Immunology
Background:
- Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions.
- Thymectomy is a standard treatment for myasthenia gravis.
- Minimally invasive surgical approaches are being explored to improve outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of subxiphoid thoracoscopic thymectomy in patients with myasthenia gravis.
- To assess the rate of complete stable remission and postoperative complications.
Main Methods:
- Retrospective review of 37 consecutive patients undergoing subxiphoid thoracoscopic thymectomy.
- Analysis of postoperative outcomes, including myasthenia gravis crisis and residual tissue.
- Assessment of neurological outcomes and remission status.
Main Results:
- Subxiphoid thoracoscopic thymectomy was technically feasible.
- Two cases of postoperative myasthenia gravis crisis and four cases of residual mediastinal fat were observed.
- Complete stable remission was achieved in 5 out of 29 evaluated patients (17.2%).
Conclusions:
- Subxiphoid thoracoscopic thymectomy is a technically feasible procedure for myasthenia gravis.
- The current evidence suggests a low rate of complete stable remission.
- Further high-quality research is required to establish the efficacy of this approach.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
01:27Pneumothorax-II
467
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
467
01:15Myasthenia Gravis: Diagnostic Tests
1.5K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.5K